Slide 1: Q1 2019 Results
Q1 2019 Results DIASORIN SPA May 9, 2019
Slide 2: Disclaimer
Disclaimer These statements are related, among others, to the intent, belief or current expectations of the customer base, estimates regarding future growth in the different business lines and the global business, market share, financial results and other aspects of the activities and situation rela
Slide 3: Highlights
Highlights COMPANY GUIDANCE Q1’19 @ curr @ CER FY 2019 at CER(*) compared to 2018 REVENUES €/mln 170.8 +3.8% +1.4% REVENUES Growth between +5.0% and + 8.0% CLIA EX VIT D TESTS +9.2% +7.8% EBITDA Comparable to 2018 EBITDA margin result VIT D TEST (CLIA) +2.1% -2.1% (°) 2018 €/US$ avg. exchange rate =
Slide 4: Q1 2019 revenues growth
Q1 2019 revenues growth Q1’19 vs. Q1’18 Q1’19 vs. Q1’18 @ curr +3.8% EUROPE & AFRICA +6.1% Total Group revenues @ CER +1.4% CLIA sales increase (Infectious diseases and Bone disease panels + Italy +22.8% Vitamin D and Latent Tuberculosis) Growth in CLIA sales (Infectious diseases, Hepatitis and Endo
Slide 5: Q1 2019 revenues breakdown
Q1 2019 revenues breakdown by geography by technology Instruments & other revenues Q1’18 Q1’18 U.S. and Canada 11.1% 29.4% Molecular diagnostic tests Europe & Africa 11.1% 46.9% CLIA tests 64.4% ELISA tests 13.4% Asia Pacific 17.4% Latin America 6.3% Q1’19 Q1’19 Instruments & other revenues U.S. and
Slide 6: Installed base expansion
Installed base expansion 7,501 7,623 7,734 7,849 7,952 +491 3,634 +123 3,757 +128 3,885 +116 4,001 +124 4,125 LAS 3,867 -1 3,866 -17 3,849 -1 3,848 -21 3,827 -40 @ March 31, 2018 @ June 30, 2018 @ Sept 30, 2018 @ Dec 31, 2018 @ March 31, 2019 Q1 2019 Results 6
Slide 7: Q1 2019 profitability profile
Q1 2019 profitability profile Q1’18 Q1’18 Q1’19 Change % EBITDA (€/MLN) 63.3 67.5 +6.6% @ CER +3.4% EBITDA MARGIN 38.5% 39.6% +105 bps @ CER 39.3% +79 bps FY’19 EBITDA upward as result of: • Increase in Gross Profit due to a favorable product and geographic sales’ mix • Positive contribution from IF
Slide 8: Investor Day 2019-2022
Investor Day 2019-2022 On June 10, 2019 Following the Board of Directors relevant approval, the press Release on 2019 – 2022 Industrial Plan will be among others available in the Investors section of the www.diasoringroup.com website On June 11, 2019 2019 – 2022 Industrial Plan presentation: 2.30 p.
Slide 9: Financial schemes
Financial schemes 9
Slide 10: Income Statement
Income Statement Q1 Change Data in € million 2018 2019 amount % Net revenues 164.5 170.8 +6.3 +3.8% Gross profit 111.2 118.6 +7.4 +6.7% Gross Margin 67.6% 69.5% +186 bps S&M (31.7) (34.5) -2.8 +9.0% R&D (11.7) (11.7) +0.0 -0.1% G&A (15.1) (17.2) -2.1 +13.8% Total operating expenses (58.5) (63.4) -4.
Slide 11: Balance Sheet
Balance Sheet Data in € million 12/31/18 03/31/19 Change Goodwill and intangibles assets 373.1 376.7 +3.6 Property, plant and equipment 95.0 128.3 +33.3 Other non-current assets 23.0 24.1 +1.1 Net working capital 201.0 208.1 +7.1 Other non-current liabilities (62.7) (60.8) +1.9 Net Invested Capital
Slide 12: Cash Flow Statement
Cash Flow Statement Q1 Data in € million Change 2018 2019 Cash and cash equivalents at the beginning of the period 159.3 73.1 -86.2 Operating activities 37.6 48.0 +10.4 Investing activities (10.0) (12.9) -2.8 Financing activities (3.5) (10.0) -6.5 Acquisitions of companies and business operations (3
Slide 13: DiaSorin
DiaSorin jt our new website www.diasoringroup.com